Paschke R, Heine M
Hepatogastroenterology. 1985 Dec;32(6):273-5.
Hepatic Veno-occlusive Disease (VOD) and Budd Chiari syndrome (BCS) have been reported as fatal complications of Dacarbazine therapy. Peripheral eosinophilia and eosinophilic infiltrates after repeated Dacarbazine therapy in some cases were interpreted as evidence of an allergic drug reaction. Since no mention of an allergic drug reaction is to be found in other reports on veno-occlusive disease or Budd Chiari syndrome due to Dacarbazine, the pathophysiological mechanism of these fatal complications of Dacarbazine remain to be elucidated. We describe a case of VOD due to Dacarbazine which showed peripheral eosinophilia after the first cycle of Dacarbazine treatment with no prior possibility of sensibilization, along with signs of a toxic drug reaction. This observation suggests that peripheral eosinophilia, so far interpreted as a sign of an allergic reaction induced by Dacarbazine, can be observed together with obvious signs of toxic drug reaction, thus providing further evidence of a toxic mechanism of Dacarbazine-induced VOD or BCS.
肝静脉闭塞病(VOD)和布加综合征(BCS)已被报道为达卡巴嗪治疗的致命并发症。在一些病例中,重复使用达卡巴嗪治疗后出现外周嗜酸性粒细胞增多和嗜酸性粒细胞浸润,被解释为药物过敏反应的证据。由于在其他关于达卡巴嗪所致静脉闭塞病或布加综合征的报告中未提及药物过敏反应,达卡巴嗪这些致命并发症的病理生理机制仍有待阐明。我们描述了1例因达卡巴嗪导致的VOD病例,该病例在首次接受达卡巴嗪治疗周期后出现外周嗜酸性粒细胞增多,且此前无致敏可能,同时伴有药物毒性反应的体征。这一观察结果表明,外周嗜酸性粒细胞增多,迄今为止被解释为达卡巴嗪诱导的过敏反应体征,可与明显的药物毒性反应体征同时出现,从而为达卡巴嗪诱导的VOD或BCS的毒性机制提供了进一步证据。